Monday 8 July 2024

New Study Confirms Forever Chemicals Are Absorbed Through Human Skin


A new study on widespread “forever chemicals” by the University of Birmingham published in Environment International proved for the first time that a wide range of PFAS chemicals can be readily absorbed through human skin. Although the chemicals are already well known to enter the body through other means such as ingestion (eating and drinking) and inhalation, it has until recently been thought that PFAS are unable to breach the skin barrier. The new study, however, confirms that most of them can enter the body via this route.  

Dr. Oddny Ragnarsd├│ttir, the lead author of the study, stated: “The ability of these chemicals to be absorbed through skin has previously been dismissed because the molecules are ionized. The electrical charge that gives them the ability to repel water and stains was thought to also make them incapable of crossing the skin membrane”. The research instead shows that this theory does not always hold, and significant amounts of PFAS exposure can be a result of absorption through the skin.  

Among the thousands of different types of PFAS, the researchers chose 17 of the most widely used and studied, and those that directly corresponded to chemicals specifically regulated by the EU’s Drinking Water Directive. Of the 17 tested PFAS, 15 showed substantial absorption of at least 5% of the exposure dose. The study also showed that absorption correlated with carbon chain length, with longer chain molecules absorbing less than shorter chain molecules. This study provides much needed evidence of how skin contact and carbon chain length can affect exposure and raises several questions at a time when industry is shifting towards shorter chain PFAS believing them to be less toxic. 

Tuesday 2 July 2024

Chemical Makers Sue Over Rule to Rid Water of ‘Forever Chemicals’

Unsurprisingly, in the wake of new PFAS regulations, some in the industry are pushing back against the tough new treatment standards.

Great story in the New York Times on the topic: https://www.nytimes.com/2024/06/10/climate/pfas-forever-chemicals-lawsuit.html

On June 10, the New York Times reported a lawsuit by several chemical and manufacturing groups against the federal government over the per- and polyfluoroalkyl (PFAS) “Forever Chemical” drinking water standards announced by the EPA two months prior. The groups claim that the new regulations exceed the government’s authority under the Safe Drinking Water Act by requiring municipal water systems across the country to filter out some of the synthetic chemicals to near non-detectable levels.  

While the EPA has said that the new standard will prevent serious illness and even death for thousands of people, these groups, along with some utilities, have brought challenges against the standard, questioning the science behind it and citing the potential cost of filtering out the chemicals. The American Water Works Association and the Association of Metropolitan Water Agencies believe the EPA have “significantly underestimated” the cost for treatment plants to meet the new standards, with the EPA estimating about $1.5 billion annually to comply and utilities claiming it could cost twice that amount.  

Ahead of the filing, Brenda Mallory, chair of the White House’s Council on Environmental Quality, in a public address defended the administration’s standards, stating: “Everyone should be able to turn on the tap and know that the glass of water they fill is safe to drink”. EPA officials also stated that the standard was based on the best available science and designed to be, “robust enough to withstand litigation”.
 

Thursday 20 June 2024

BioLargo Engineering Increases Ongoing Revenue with Another Air Force Contract

USAF work now amounts to over $100,000 in revenue per month.

Westminster, CA – June 20, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a subcontract to provide air quality services to two Arizona U.S. Air Force bases for up to four years, with expected annual revenue of approximately $812,000.

The news comes on the heels of a similar recently announced contract award to serve three Air Force bases in New Mexico, which has a potential annual average revenue of $650,000. BioLargo’s work at the Arizona bases consists primarily of the air quality regulatory compliance portion of a Fence-to-Fence (F2F) support contract through prime contractor HLTLI Joint Venture, LLC, a joint venture between HL Environmental Services and TLI Solutions.

The four-year prime contract secures pricing for F2F services over the term of the contract but does not guarantee continuation of the contract over that duration. In the past, BioLargo’s engineers have continued providing services through the duration of the prime contract. In total, BioLargo Engineering’s work at Air Force bases now amounts to over $100,000 of revenue per month.

BioLargo Engineering, Science & Technologies President Randall Moore commented, “We are pleased and honored to continue providing vital engineering services to the United States Air Force and supporting their active mission and environmental compliance needs. These new contracts will provide for over $100,000 a month of ongoing fixed revenues while we continue to expand our abilities to support new opportunities.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday 12 June 2024

BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products

Westminster, CA – June 12, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. (“Clyra”) has selected Keystone Industries, a global manufacturer of medical, dental and cosmetic products with distribution partners in more than 70 countries, to support manufacturing of its medical products. The relationship focuses on the build-out of scaled manufacturing capacity for Clyra’s FDA 510(k) cleared Bioclynse surgical wound irrigation solution. Clyra and Keystone have been and continue to make significant investments to support the launch of Bioclynse.

Bioclynse is Clyra’s FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:

  • Non-cytotoxic, non-sensitizing, no damage to tissue
  • No rinse-out required
  • Non-staining
  • Sustained multi-day efficacy
  • Effective against biofilms

Cary Robinson, President and CEO of Keystone Industries, said, “We are excited to support Clyra Medical Technologies to bring Bioclynse to the market. Keystone has a century of experience in developing and manufacturing medical device, OTC and pharmaceutical products. We have committed a significant investment in our infrastructure to support the manufacturing of innovative products like Clyra’s Bioclynse and can readily provide the needed support to scale up production rapidly.”

Steve Harrison, President of Clyra Medical Technologies, commented, “We are continuing to work hard and spend money to support the scaled roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing partner willing to invest significant money in new equipment and dedicated space was critical to these efforts. We look forward to a long and mutually prosperous relationship with Keystone.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Keystone Industries, Inc.

Keystone Industries is a market leader with over 100 years experience in developing cosmetic, medical device, OTC and pharmaceutical products. The company operates through a diverse network of over 800 U.S. and international distribution partners in more than 70 countries. Keystone maintains FDA licensing, ISO 13485 (medical device) and 22716 certifications, as well as GMP certification and international product registrations. Keystone’s commitment to innovation and quality ensures that the company consistently exceed the evolving needs of their customers. See our website at www.keystoneindustries.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday 11 June 2024

BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion

Westminster, CA – June 11, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first CellinityTM “Liquid Sodium” prototype battery cells. Visit www.BioLargoEnergy.com to learn more.













Cellinity is BioLargo’s next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery – rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry. These newly manufactured Cellinity prototype cells will now be tested and validated for the energy storage and transfer performance claims that were generated in the technology’s early-stage research and development by its original inventors:

  • Far greater safety – no runaway fires, no risk of explosion;
  • Extremely long-lasting – no performance decrease over thousands of cycles;
  • No self-discharging, no out-gassing, and no parasitic load for cooling;
  • High energy density – more energy per unit of weight than lithium batteries;
  • All materials can be sourced within North America without the need for rare-earth elements.

“Successfully manufacturing our first battery cells is a pivotal moment in the journey of our battery technology,” said Dennis P. Calvert, President and CEO of BioLargo. “The testing and validation of these cells will allow us make claims about the capacity, charge/discharge rate, and other performance characteristics that we believe differentiate our batteries in the marketplace. After testing and validation, we will manufacture full-scale prototype Cellinity battery modules in 25- and 45-kilowatt hour capacities for further testing and validation.”

He continued, “In parallel to our ongoing development of the Cellinity battery, we’re exploring various financing options that ensure we get paid for and are in control of the engineering and construction of manufacturing facilities. Although initial discussions have taken place, we have no agreements in place. We believe a licensing and partnership model to be a better alternative to self-financed and self-operated manufacturing facilities competing with the likes of Tesla, and well suited for community-based manufacturing partners focused on underserved communities that are in special need of reliable renewable energy. Our target projects will add value to communities, develop workforces, stimulate economic development, promote grid stability and enable the development and expansion of micro-grids around the world. We will fundamentally enable and enhance the adoption of renewable energy.”

Mr. Calvert finished by saying, “The world needs a reliable, safe and eco-friendly alternative to lithium batteries, and we believe our Cellinity battery will meet these needs.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday 7 June 2024

BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project







Westminster, CA – June 7, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a contract to provide air quality services to three New Mexico U.S. Air Force (USAF) bases for up to five years, with a potential annual average revenue of $650,000.

The new contract is in addition to ongoing environmental support work at six Air Force bases and is the company’s largest dollar-value Air Force contract to date. These contracts provide regularly monthly flat fee revenue to the company over the life of the contract, which the Air Force may renew each year. BioLargo’s work at the New Mexico bases includes air quality regulatory compliance. Bhate Environmental Associates is the prime contractor with the Air Force under the Fence-to-Fence (F2F) support contract.

BioLargo Engineering, Science & Technologies President Randall Moore commented, “Our team has served Air Force bases with fence-to-fence air quality compliance services for years, but this is the largest such contract we’ve secured to-date. Larger, long-term contracts such as this one are crucial to our strategy of securing steady, reliable income from external clients. This empowers us to focus on commercializing BioLargo’s innovative cleantech technologies, including advancements in water treatment, energy storage, and air quality solutions.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Bhate Environmental Associates, Inc.

Bhate Environmental Associates, Inc. (Bhate) provides a diverse range of technical services in the environmental and infrastructure markets to the federal government and private industry. Headquartered in Birmingham, Alabama, Bhate’s reach is both national and global. At Bhate, we value high standards of safety, professionalism, ethics, and service to our clients. We foster a collaborative environment that encourages innovative ideas while providing challenges and rewards for our dedicated staff. Through our team’s Responsiveness, Integrity, and Teamwork, Bhate delivers professional, quality, cost-effective, and on-time results to our clients. See their website at www.Bhate.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday 14 May 2024

BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024

Westminster, CA – May 14, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that the company generated $481,000 operating cash flow with record quarterly revenues of $4,760,000 for the three months ended March 31, 2024. The company filed its quarterly report on Form 10-Q with full financial results, available at www.biolargo.com/sec-filings.  

BioLargo will hold an investor webcast on Tuesday May 14, 2024, at 2:30 pm Pacific Time, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/50622   

BioLargo’s President and CEO Dennis P. Calvert discussed the results of the quarter, “We’ve had several years in a row of exceptional revenue growth, and as a result generated positive cashflow from operations this past quarter. Our goal, of course, is positive net income, and results like these bring us closer to achieving that goal.”

He continued, “BioLargo is executing on a winning formula: a team of highly qualified people dedicated to inventing, proving, and partnering to capitalize on a diversified portfolio of transformative technologies with the potential to create real change in the world.”

Financial highlights from the first quarter of 2024:

  • Companywide revenue for the three months ended March 31, 2024, grew to $4,760,000, a 9% increase over the fourth quarter of 2023 and a 28% increase over the first quarter of 2023.
  • The company generated positive cash from operating activities (cashflow) of $481,000, compared with negative $2,000 in the fourth quarter of 2023.
  • The company’s net stockholder’s equity increased from $4.2 million to $5.1 million.
  • Net loss was $775,000, a 32% decrease compared to the previous quarter and a 57% increase compared to the same period of 2023. Net loss included $623,000 in non-cash equity compensation expenses.

Business highlights from the first quarter of 2024:

  • Launched water equipment subsidiary to capitalize on opportunities in PFAS and water treatment.
  • Appointed key industry leaders to board of water equipment subsidiary: Sally Gutierrez, former U.S. EPA Senior Advisor for Water; Jeffrey Kightlinger, recognized water industry leader; and Larry Dick, former Vice Chairman of the board of Metropolitan Water District of Orange County.
  • The U.S. EPA finalized two important sets of regulations on PFAS that will influence the growth of the PFAS treatment market and may disproportionately favor our PFAS treatment technology because of its high efficacy against all types of PFAS and its low rate of production of solid PFAS-laden waste as a treatment byproduct.
  • Clyra is making substantial investments for scaled-up distribution of its Bioclynse line of products and contracting with third parties for FDA-compliant product manufacturing.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday 10 May 2024

BioLargo Q1 2024 Earnings Results Webcast and Conference Call on Tuesday, May 14, 2024 - 5:30 PM Eastern Time

WESTMINSTER, CA /  May 10, 2024 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced it will host an investor webcast and conference call on Tuesday, May 14, 2024, at 2:30 pm Pacific / 5:30 pm Eastern. The event, which will be open to the public, will be held to review the company's financial results for the three months ending March 31, 2024, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/50622

Teleconference Domestic: 877-545-0523

Teleconference International: 973-528-0016

Participant Access Code: 447613

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Sunday, July 14, 2024

Teleconference Replay Expiration: Tuesday, May 28, 2024

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 50622

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo's website at www.biolargo.com/investor-relations.


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday 23 April 2024

EPA Adds PFAS to CERCLA (Superfund) Law, Favoring Low-Waste Systems like BioLargo’s AEC

BioLargo’s PFAS treatment technology generates a fraction of the waste compared to carbon filtration

Westminster, CA – April 23, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today provided commentary on the importance of a final decision by the U.S. Environmental Protection Agency (EPA) to regulate two per- and polyfluoroalkyl substance (PFAS) chemicals as “hazardous substances” under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as the Superfund law. BioLargo’s PFAS treatment solution, the Aqueous Electrostatic Concentrator, generates a small fraction of the volume of PFAS-laden waste that carbon filtration systems generate, thus reducing operational costs of waste handling, transport, and disposal.

In the EPA press release, EPA Administrator Michael S. Regan stated, “Designating these chemicals under our Superfund authority will allow EPA to address more contaminated sites, take earlier action, and expedite cleanups, all while ensuring polluters pay for the costs to clean up pollution threatening the health of communities.” These new regulations come on the heels of the EPA’s announcement two weeks ago setting PFAS drinking water limits as low as four parts per trillion.

This new EPA action also means that these PFAS chemicals will be listed as “hazardous materials” under the Hazardous Materials Transportation Act, which will require materials containing these chemicals to be transported using special protocols.

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc., which markets BioLargo’s PFAS treatment systems, commented, “We believe these and other upcoming regulations create a price advantage for our AEC system over competing sorbent technologies such as carbon filtration. With less waste generated, we can also offer clients waste handling all the way through to full destruction at our facility.”

These finalized CERCLA regulations are the most recent step by the EPA to limit exposure of Americans to PFAS. In addition to the recently announced federal drinking water standards for six PFAS chemicals, the agency also committed $9 billion in funding to help communities and water providers address contamination by PFAS and other emerging contaminants. This funding will assist communities and water providers to acquire PFAS monitoring and treatment systems to comply with new regulations.

Dennis P. Calvert, President and CEO of BioLargo, commented, “We’re pleased to see the U.S. government taking PFAS seriously and dedicating the billions of dollars in funding needed to protect municipal water supplies across the country.” 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. Its website is www.biolargoequipment.com. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday 15 April 2024

BioLargo PFAS Removal Technology Meets New US Drinking Water Standards

BioLargo’s Aqueous Electrostatic Concentrator generates a fraction of the waste product of competing technologies

Westminster, CA – April 15, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, confirmed that its Aqueous Electrostatic Concentrator (AEC) can remove per- and polyfluoroalkyl substances (PFAS) from water to meet and surpass the U.S. Environmental Protection Agency (EPA) drinking water limits for PFAS chemicals announced April 10, 2024. Additionally, the AEC produces far less PFAS-laden solid waste than carbon filtration or ion exchange, which should result in lower long-term costs for customers while reducing potential regulatory burden. BioLargo also offers advisory services, analytical testing, and education on PFAS science and regulations to water providers who need assistance complying with the new regulations. The newly finalized rules set national limits for PFAS in public drinking water to nearly undetectable levels, as low as 4 parts per trillion.

PFAS are an expansive group of man-made chemicals used for decades in the manufacture of countless goods, including non-stick cookware, fast-food containers, and firefighting foam. PFAS have been linked to numerous health problems including cancer and developmental issues, and are challenging to remove from water using traditional treatment techniques.

While traditional water filtration treatment technologies such as granular activated carbon, ion exchange, and membrane filtration may meet these new EPA standards on some PFAS species, they can fall short of achieving sufficient removal rates for short-chain PFAS molecules (such as the now-EPA-regulated GenX and PFHXS). They also have the significant downside of producing large volumes of PFAS-laden solid waste, which requires additional disposal costs and creates potential regulatory liability.

These new EPA regulations mark a shift in the evolving market for PFAS treatment technologies. Previously driven by a patchwork of state and local drinking water regulations, drinking water providers across the country will have to comply with the new federal standards. The EPA estimates compliance with the new rules will cost approximately $1.5 billion annually; spending in other industry segments is not included in that estimate (e.g., treatment of groundwater, wastewater, industrial wastewater, or landfill leachate).

“These long-awaited drinking water regulations are a big win for our technology,” commented Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, BioLargo’s water equipment subsidiary. “Our AEC has an edge over the competition, as it can meet these new standards for all PFAS contaminants and generates far less PFAS-laden waste requiring disposal.”

In addition to these new standards, in February 2024 the EPA proposed changes to the Resource Conservation and Recovery Act regulations by adding nine PFAS chemical compounds to its list of hazardous constituents in Title 40 of the Code of Federal Regulations Part 261 Appendix VIII.

“If these RCRA rules are finalized, costs associated with handling and disposing of PFAS-laden solid waste will likely become more expensive and difficult, giving our product a significant cost advantage over the competition,” said Ms. Chandler.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. Its website is www.biolargoequipment.com. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday 2 April 2024

BioLargo achieved 108% year-over-year revenue growth in 2023

Westminster, CA – April 2, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its Annual Report, filed April 1, 2024, showed the company’s annual revenues increased by 108% year-over-year compared to 2022 (www.biolargo.com/sec-filings).

BioLargo will hold an investor webcast on Tuesday, April 2, 2024, at 2:00 pm Pacific / 5:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/50271   

Dennis P. Calvert, the company’s President and CEO, commented, “Rising odor control product sales continue to push our business forward. We are confident that our PFAS solutions will find additional traction in 2024 and believe they will eventually contribute significantly to our overall growth trajectory. Almost cash-flow positive in the fourth quarter of 2023, we continue to focus our business on leveraging our intellectual property and partnering with great companies to scale up sales and distribution while preserving capital and human resources.”

The following are select highlights from BioLargo’s annual report filed April 1, 2024, and are not a substitute for the details in the 10-K, which can be found here (https://www.biolargo.com/sec-filings). All interested parties are encouraged to review the full report filed with the SEC, including the risk factors at page 9, to get the most complete information about BioLargo and its growing cleantech business.

Financial highlights from the annual report:

  • Revenues for the year ended December 31, 2023, were $12,230,000, a 108% increase over 2022.
  • Revenues in the fourth quarter of 2023 were $4,370,000, a 64% increase as compared with the third quarter of 2023 (quarter-over-quarter), and a 108% increase as compared with the fourth quarter of 2022.
  • Cash flow from operations for the year was negative $2,365,000.
  • The company’s net loss for the year ended December 31, 2023, was reduced by 9% as compared with the prior year, from $5,132,000 to $4,648,000. More than 60% of the company’s net loss was due to non-cash expenses, including $2,124,000 of stock option compensation expense, and $384,000 of services paid by the issuance of our common stock.
  • 21% of the company’s total operating expenses in 2023 were from research and development, up from 16% in 2022, as we built out a facility to manufacture and test our first batteries.
  • Total stockholders’ equity more than doubled - from $2,011,000 at December 31, 2022, to $4,202,000 at December 31, 2023.
  • Total assets as of December 31, 2023 were $8,205,000, against total liabilities of $4,003,000.
  • The company ended the year with working capital of $3,652,000.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday 1 April 2024

BioLargo Year-End 2023 Earnings Results Webcast and Conference Call on Tuesday, April 2, 2024 – 5:00 PM Eastern Time

Westminster, CA – April 1, 2024– BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Tuesday, April 2, 2024, at 2:00 pm Pacific / 5:00 pm Eastern. Open to the public, the webcast will be held to review the company’s financial results for the year ending December 31, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.


To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/50271

Teleconference Domestic: 877-545-0523

Teleconference International: 973-528-0016

Participant Access Code: 614240


To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Tuesday, July 02, 2024

Teleconference Replay Expiration: Tuesday, April 16, 2024

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 50271

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Monday 25 March 2024

BioLargo to Present at The LD Micro Invitational XIV

 Westminster, CA, March 25, 2024--(Newsfile Corp.) – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced today that it will be presenting at the 14th annual LD Micro Invitational investor conference on April 9, 2024, at 2:30 PM ET, at the Sofitel New York hotel. Dennis P. Calvert, President and CEO of BioLargo, will be giving the presentation.

Mr. Calvert’s presentation will focus on the company’s 2023 financial results, in which revenues more than doubled from 2022, as well as the progress of multiple commercial initiatives including consumer pet odor control, the company’s liquid sodium battery energy storage system, and the company’s PFAS water treatment business. 

We invite interested parties to register to watch BioLargo’s presentation virtually here: https://ldinv14.sequireevents.com/ 


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  

About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

Please reach out to the company representative below or Dean Summers (dean@ldmicro.com) to register for the event or schedule a meeting with BioLargo. 

To learn more about Freedom US Markets, visit www.freedomusmkts.com


For further information on BioLargo, Inc.:

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

dennis.calvert@biolargo.com

www.biolargo.com 


Friday 22 March 2024

PFAS Regulatory Hearings in the Senate – Our Take

For those unaware, the Senate held a hearing this week regarding regulating per- and polyfluoroalkyl substances (#PFAS) under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). If this happens, sites badly contaminated by PFAS would be subject to enforcement under CERCLA, meaning those parties responsible for the contamination would have to pay for its cleanup. This proposal is separate from the proposals to regulate PFAS under the Safe Drinking Water Act (which would require drinking water treatment plants to monitor and treat for PFAS) and the Resource Conservation and Recovery Act (which would create rules to treat PFAS-containing substances as hazardous constituents).

At BioLargo, obviously we have strong opinions in this situation (we’re selling PFAS treatment solutions!), but we think most people will agree that regulating PFAS under CERCLA is good thing. Why? Because it will help ensure that these badly contaminated lands get remediated, and protect future generations from these damaging contaminants. It will also hold polluters responsible, and create a budget for sites to get cleaned up (and as a reminder, if a polluter can’t be identified, the “superfund” helps pay for its cleanup). Finally, regulating PFAS under CERCLA is an admission that PFAS is a problem that demands a solution that is  “cradle-to-grave”, meaning you shouldn’t just sequester PFAS in a landfill somewhere.

The Senate meeting this week was held to discuss the potential for creating a carve-out exception under the proposed CERCLA PFAS rules for “passive receivers”, which are sites or facilities that receive PFAS-containing materials incidentally, rather than it being something they generate as part of their business. Examples of passive receivers include wastewater treatment facilities and landfills. The hearing helped illuminate how the federal government is looking at tackling the issue of PFAS-contaminated sites, and how they hope to hold polluters responsible while not causing undue collateral damage.

Some highlights from the hearing:

  • The committee’s main concern was that “passive receivers” of PFAS-containing materials might be on the hook for PFAS cleanup if the chemicals are regulated under CERCLA with no provisions to protect them.
  • Handling of PFAS-laden wastes, and the costs associated with that waste, was a concern to committee members.
  • Members of the committee mentioned that carbon filtration and ion exchange are the ”best available” treatment options – from our perspective, this is basically the government acknowledging that GAC and ion exchange are the only technologies already available (so far) at large-scale to solve the problem, even though they’re in many ways not ideally suited to treat PFAS. These technologies have real downsides: they have “blind spots” of short-chain PFAS species that they struggle to remove, and they generate a lot of solid waste in the process of treatment.  We believe these solutions will fall short in the long run!
  • While the committee was split on the particulars of who should be held responsible for PFAS contamination and how, no one argued that PFAS isn’t dangerous and shouldn’t be treated.

It’s at this point that we have to remind everyone that BioLargo’s PFAS treatment solution, the Aqueous Electrostatic Concentrator (AEC) is an ideal solution to treat PFAS in a post-CERCLA regulations world. Why? Because the AEC is designed from the ground up to concentrate PFAS onto an extremely small surface area – meaning it creates far less PFAS-laden waste than things like ion exchange or carbon filtration.

We stand ready to help industry and passive receivers clean up their water, as well as their waste streams including wastewater and leachate, and help them minimize their CERCLA liability exposure.

As the situation regarding PFAS regulations evolve, we’ll try to keep people updated! I will be presenting next week at the MWEA/AWWA 2024 Join Annual Meeting about these topics, and several other events throughout the summer.

$BLGO #PFAS #BestPFASSolution

- Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc.

www.biolargoequipment.com

Tuesday 20 February 2024

BioLargo adds Larry Dick, prominent water industry veteran, to board of its water equipment subsidiary

Larry Dick
Westminster, CA – February 20, 2024 – BioLargo, Inc. (OTCQB:BLGO), a cleantech developer that creates innovative technologies to solve demanding environmental challenges, announced that Larry Dick, a member of the board of directors of the Municipal Water District of Orange County, California (MWDOC) and former Vice Chairman of the board of the Metropolitan Water District of Southern California (MWDSC), has joined the board of directors of its water equipment subsidiary (BioLargo Equipment Solutions & Technologies; www.bestPFAStreatment.com). Larry brings his relationships and years of experience in water management to help BioLargo commercialize its portfolio of innovative, sustainable water treatment technologies, including its revolutionary technology to treat water contaminated with per- and polyfluoroalkyl substances (PFAS).

Over the past 20 years, Larry has held leadership positions including Vice Chairman at the MWDSC, the largest drinking water agency in the United States. Throughout that time, he also served as President of the Board of Directors of MWDOC and held positions at the Association of California Water Agencies, the Water Advisory Committee of Orange County, and the Urban Water Institute. He is a dedicated public servant committed to delivering safe, sustainable, affordable water to Californians.

In joining the board of BioLargo’s equipment subsidiary, Larry brings long-established business relationships and connections in the water industry as BEST begins to commercialize its innovative water treatment solutions. He aims to help build the company’s reputation and secure new partnerships and opportunities for growth in the Southern California area.

Larry commented, “Improving the quality and access of Americans’ water has been my life’s work for the past two decades. I joined the board of BioLargo’s water equipment and PFAS solutions company because of how clear to me it is that this same mission – improving and safeguarding our water – is a core value for all their team members.” 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. Its website is www.bestPFAStreatment.com. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday 12 February 2024

BioLargo Recruits Sally Gutierrez, Former EPA Senior Advisor, for the Board of its Water Equipment and PFAS Solutions Company

Sally Gutierrez
Westminster, CA – February 12, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that retired career senior executive at the US Environmental Protection Agency Sally Gutierrez has joined the board of directors of its subsidiary BioLargo Equipment Solutions & Technologies, Inc. Ms. Gutierrez will bring over thirty years of experience developing water regulations at the state and federal level to the BioLargo team to assist the company in its efforts to commercialize its innovative water treatment technologies for emerging contaminants such as per- and polyfluoroalkyl substances (PFAS).

Ms. Gutierrez has been a career senior executive for the EPA for over twenty years. She has held key positions within the EPA, primarily within its Office of Research and Development (ORD). She has held the title of Director for numerous offices within the EPA’s ORD, including the Environmental Technology Innovation Cluster Development and Support Program, the National Risk Management Research Laboratory (NRMRL), and the NRMRL Water Supply and Water Resources Division. She also served as a Senior Water Advisor for the ORD Center for Environmental Solutions and Emergency Response and the Acting Director of the Water Permits Division within the EPA’s Office of Wastewater Management in Washington, DC. 

In joining the board of BioLargo Equipment Solutions & Technologies, Ms. Gutierrez will assist the company in achieving expanded adoption of its innovative technologies in the water industry by helping navigate the rapidly changing regulatory environment surrounding newer issues in water treatment such as PFAS contamination. 

Ms. Gutierrez was drawn to join the company’s board specifically because of the significant potential for its innovative PFAS treatment solutions to safeguard American drinking water and remediate badly contaminated water around the country, an issue she says is deeply important to her.  “Of all the environmental challenges I have tackled in my career, PFAS contamination is one of the most serious public health issues,” Ms. Gutierrez commented. “BioLargo’s AEC technology stands apart as a solution that offers an effective alternative to more traditional technologies for management of PFAS especially in regard to waste generation.”

“My goal is to help BioLargo bring its PFAS treatment solution to communities across the country and make sure that every American city and town has access to safe drinking water,” said Ms. Gutierrez.

Read more about BioLargo’s PFAS treatment solutions at www.bestpfastreatment.com. 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Monday 5 February 2024

Jeffrey Kightlinger, Recognized Water Industry Leader, Joins Board of BioLargo’s Water Equipment and PFAS Solutions Company

Jeffrey Kightlinger
Westminster, CA – February 5, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that Jeffrey Kightlinger, former CEO of the Metropolitan Water District of Southern California, has joined the board of directors of its water equipment and PFAS solutions company BioLargo Equipment Solutions & Technologies. Recently announced, the subsidiary was launched to facilitate the sales, marketing, and distribution of BioLargo’s innovative water treatment technologies, such as its effective, low-waste PFAS treatment system.

Mr. Kightlinger is renowned for his distinguished service as the longest-serving CEO of the Metropolitan Water District of Southern California, the nation’s largest municipal water provider serving over 19 million Californians. During his tenure, Mr. Kightlinger oversaw a $1.8 billion budget, and was responsible for delivery of reliable, safe water to over 300 cities, including the counties of Los Angeles, Orange, Riverside, San Bernadino, San Diego, and Ventura. He was integral in establishing some of MWDSC’s world-renowned water technology innovation programs. Mr. Kightlinger is a recognized subject matter expert on the topics of water conservation, quality, and stewardship, and is often interviewed by major water industry publications and magazines.

Mr. Kightlinger will contribute his decades-long experience in municipal water management to support BioLargo Equipment Solutions & Technologies by connecting the company with other leaders in the nation’s water industry, and by advising the company in its efforts to secure larger and more high-profile municipal water treatment projects for its proprietary treatment technologies.

He agreed to join the company’s board in part because of recent news surrounding BioLargo’s innovative, effective, and sustainable water treatment solution for drinking water contamination by per- and polyfluoroalkyl substances (PFAS), commonly known as "forever chemicals”. BioLargo recently secured a contract to install its PFAS removal technology at a drinking water system in New Jersey and intends to secure additional drinking water treatment projects in the coming year.

Mr. Kightlinger commented, “I am honored to join the board of BioLargo Equipment Solutions & Technologies, and hope that my experience in municipal water management can propel its innovative products such as its PFAS removal system the AEC.”

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, said, “Our water treatment solutions are unique and remarkable in their technical claims and performance, and it is critical to have the right leaders on board to help guide the company to make the greatest impact in the water industry. We’re honored to have Jeffrey join our board, as his past accomplishments in the water industry have been hugely impactful in California.”

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday 29 January 2024

BioLargo Launches Water Equipment Subsidiary to Capitalize on Opportunities in PFAS and Water Treatment

Westminster, CA – January 29, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced the launching of a new subsidiary – BioLargo Equipment Solutions & Technologies, Inc. (BEST) – to capitalize on substantial opportunities for its technologies in the water treatment industry. BEST will enable BioLargo to represent all its water technologies under one roof, better support its sales and distribution network of qualified reps and channel partners, and will initially focus on: 

  • the AEC, an effective, sustainable, low-waste technology for removing per- and polyfluoroalkyl substances (PFAS) from water which is combined with a turnkey collection and destruction solution for customers;
  • the AOS (Advanced Oxidation System), a technology targeted at energy-efficient water disinfection and micropollutant destruction;
  • the AROS (Aqueous Reuse Optimization System), a water recycling technology for use in cooling towers and industrial wastewater that was developed in partnership with Garratt-Callahan;
  • industrial odor control products under the CupriDyne brand offered by sister company ONM Environmental; and
  • water treatment solutions developed by third party technology manufacturers for which BEST is an authorized reseller in order to provide complete solutions for its customers.

Tonya Chandler, BioLargo’s Director of Technical Commercialization, has agreed to move into the role as president of the new subsidiary. Tonya has over 20 years’ experience developing selling channels and managing complex projects and accounts in the water industry and is ideally suited to lead efforts to sell and monetize BioLargo’s water treatment technologies. She also established herself as a recognized expert in PFAS water treatment invited to speak at numerous conferences and educational, including continuing education units for engineers, and similar events throughout the year and continuing into 2024.

Although new to the role of president of BEST, Tonya has been building a nationwide sales organization for BioLargo’s water treatment technologies, and she led the efforts to establish BEST’s pipeline of potential projects. The building of this pipeline has been demanding work. Each project goes through a rigorous process to test water and identify a solution, which is presented to the prospective client. At their request, proposed engagements include proposed engineering, pricing, timing, supply chain support and relationships, permitting, and customization as required. The pipeline continues to expand.   

Tonya commented, “The municipal drinking water project we secured in New Jersey for a PFAS treatment system is just the start for BEST. As our first opportunity to for field validation of our technology’s superior PFAS removal performance and minimal waste generation, we believe it will open the floodgates of client opportunities. We are working on commencing on-site pilots for other target markets for our PFAS technology, including fire-fighting foam remediation, ground water, wastewater and landfill leachate.”

CEO of BioLargo, Inc., Dennis P. Calvert commented, “It isn’t easy to launch new and innovative technologies into the water industry, a historically risk-averse market. Our strategy is to execute successful projects with initial reference customers, create iron-clad case studies, then foster recognition of our technologies in the industry with key opinion leaders. Tonya is perfectly suited to lead this effort and we also are actively recruiting additional team members to help us grow as we bring on and support additional customers. We look forward to sharing more information as the business progresses.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.